Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Ligand Pharmaceuticals (NASDAQ:LGND) and maintained a $95 price target for the company's stock.

December 13, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman reiterates a Buy rating on Ligand Pharmaceuticals and maintains a $95 price target.
The reiteration of a Buy rating and the maintenance of a $95 price target by a Benchmark analyst could instill confidence in investors and potentially lead to a positive short term impact on Ligand Pharmaceuticals' stock price. Analyst ratings are influential in shaping market sentiment, and a Buy rating suggests that the analyst sees the stock as undervalued or poised for growth, which can encourage investment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100